Steqeyma (ustekinumab or ustekinumab-stba) is a prescription injection that's a biosimilar to Stelara (ustekinumab). It lowers inflammation, so it's used to treat autoimmune conditions like plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The medication is most often given as an injection under the skin, typically once every 8 or 12 weeks after a few initial doses. Common side effects include common cold symptoms, headache, and tiredness.
Steqeyma (ustekinumab) is an interleukin antagonist. It works by blocking two proteins in your immune system — interleukin-12 (IL-12) and interleukin-23 (IL-23) — that play a major role in inflammation. By targeting these proteins, the medication helps to lower inflammation and relieve symptoms from autoimmune conditions.
The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.
Plaque psoriasis
Psoriatic arthritis
Crohn's disease
Ulcerative colitis:
Contact your healthcare provider immediately if you experience any of the following.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report to your care team if they continue or are bothersome):
How to inject Steqeyma (ustekinumab) from a prefilled syringe:
No. They aren't exactly the same, but they're similar. Steqeyma (ustekinumab) is a biosimilar to Stelara (ustekinumab), meaning it’s designed to work the same way. Both medications treat the same conditions by lowering inflammation. But biosimilars like Steqeyma (ustekinumab) are made by different manufacturers, which might cause small differences like packaging or inactive ingredients. If you have questions comparing the two, talk to your prescriber.
Yes. Steqeyma (ustekinumab) became available in the United States starting March 2025.
Yes. The FDA approved Steqeyma (ustekinumab) in December 2024.
Yes. Steqeyma (ustekinumab) is interchangeable with Stelara (ustekinumab) for all approved conditions. This means the FDA allows pharmacies to substitute Steqeyma (ustekinumab) for Stelara (ustekinumab) without needing a new prescription, making it easier if you and your prescriber decide to switch medications.
Yes. Steqeyma (ustekinumab) is a biologic medication. Biologic medications are made from living sources, like cells or proteins.
Steqeyma (ustekinumab) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Steqeyma (ustekinumab) can raise your risk of infections, including serious ones that might need hospital care. These can be caused by bacteria, viruses, or fungi. Tell your prescriber about your medical history before starting Steqeyma (ustekinumab), especially if you've ever had tuberculosis (TB). Let your care team know right away if you have signs of infection, such as fever, chills, cough, or tiredness — your treatment might need to be paused until you recover.
Steqeyma (ustekinumab) weakens your immune system and can raise your risk of certain cancers. Some people developed skin cancer while taking this medication, especially those with a higher risk. Your care team will check your skin regularly during treatment, particularly if you have a history of cancer or other risk factors. Let your prescriber know if you’ve had cancer before or if you notice any new or changing spots on your skin.
Serious allergic reactions, including anaphylaxis and angioedema, have been reported with Steqeyma (ustekinumab). If you have a severe reaction, your care team will stop the medication and treat you right away. Get medical help immediately if you have symptoms like trouble breathing, swelling of your face or throat, or a serious rash.
Rare cases of a brain condition called posterior reversible encephalopathy syndrome (PRES) have been reported in people taking Steqeyma (ustekinumab). Symptoms can include headache, seizures, confusion, or vision changes. These symptoms can appear anywhere from a few days to months after starting the medication, sometimes even after a year or more. If you have PRES, your care team will stop the medication and provide treatment. Let your prescriber know right away if you notice any of these signs.
Before starting Steqeyma (ustekinumab), you or your child should be up to date on all recommended vaccines. While you're being treated, avoid getting live vaccines. You should also avoid the BCG vaccine during treatment, as well as for one year before starting and one year after stopping the medication. Be careful if someone in your household gets a live vaccine since it can spread and pose a risk to you. Non-live vaccines are generally safe, but they might not work as well while you're taking Steqeyma (ustekinumab). Check with your care team before getting any vaccines during treatment.
Different types of pneumonia have been reported in people taking Steqeyma (ustekinumab), and in some cases, these conditions were serious. Symptoms can include cough and trouble breathing. Let your care team know right away if you have new or worsening breathing problems. You might have to stop taking the medication and receive the appropriate treatment.
Plaque psoriasis
Psoriatic arthritis
Crohn's disease and ulcerative colitis: